

The effect of valproic acid (VPA) on activated T lymphocytes¹

Chatsidis G MD,^a Boukas K BSc,^a Hadjigeorgiou G MD/PhD,^b Germeis AE MD/PhD,^a Karanikas V BSc/PhD^a

¹Cancer Immunology Unit, Department of Immunology and Histocompatibility, ²Department of Neurology; School of Medicine, University Hospital of Larissa

Background

VPA is an established and widely used drug for the treatment of epilepsy. Many cellular pathways are affected from VPA and recently, it was discovered that it acts as an inhibitor of histone deacetylases, regulating in this way gene expression through epigenetic mechanisms. At the same time, cells of the immune system constantly undergo a series of epigenetic alterations to respond to immune stimuli. Since VPA has been suggested to have an immunomodulatory role, and it is a drug continuously used in a variety of neurological disorders, this project was scheduled in order to investigate the functional effect of VPA on lymphocytes derived from normal individuals.

Methods

Freshly thawed peripheral blood mononuclear cells (PBMC) from 12 healthy individuals (7 males, 5 females) (mean±SD=25.3±8.7 yrs, range 17-44 yrs) were stimulated with phytohemagglutinin (PHA-L) in the presence of sub-toxic concentrations of VPA for 4 days (Figure 1). Viable cells were assessed for alterations in their cell surface phenotype as well as their cell cycle.







Figure 1

Results



Conclusion

Culture of lymphocytes in the presence of VPA has an immunomodulatory effect, coupled by an inability of cells to proliferate upon stimulation. This finding can impact on the immune response of patients treated with VPA.

REFERENCES

1. Germeis AE, Karanikas V. Immunol Cell Biol 2007, 85:55-59

This work was supported by a Marie Curie Incoming International Fellowship within the 6th European Community Framework Programme (MIF1-CT-2006-021795) grant, b) a E.U.-European Social Fund (70%) & the Greek Ministry of Development-GSRT (30%) (EPAN05 NON-EU-445) grant and c) a Marie Curie International Re-integration grant within the 6th European Community Framework Programme (MIRG-CT-2006-046459, IMMUNOEPIGENETICS)